SCHEMBL3764577

SCHEMBL3764577

Cn1nccc1NC(=O)N1CCN(c2nc(-c3ccc(F)cc3)cs2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.65
MAPT P10636 6/20 0.61
MAPK1 P28482 5/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
LMNA P02545 3/20 0.61
HTT P42858 3/20 0.61
L3MBTL1 Q9Y468 3/20 0.57
ALDH1A1 P00352 3/20 0.56
TP53 P04637 1/20 0.56
CYP1A2 P05177 2/20 0.56
CYP2C19 P33261 2/20 0.56
CYP3A4 P08684 1/20 0.53
GAA P10253 1/20 0.53
CYP2C9 P11712 1/20 0.53
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
AR P10275 2/20 0.52
MEN1 O00255 1/20 0.50
NR2F2 P24468 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773023 0.90 FAAH (0.64) FAAHMAPTMAPK1SMN1; SMN2LMNA
SCHEMBL3772080 0.89 FAAH (0.67) FAAHMAPTMAPK1SMN1; SMN2LMNA
SCHEMBL3774639 0.85 FAAH (0.67) FAAHMAPTMAPK1SMN1; SMN2LMNA
SCHEMBL3761321 0.79 FAAH (0.74) FAAHMAPTMAPK1SMN1; SMN2LMNA
SCHEMBL3778524 0.78 SMN1; SMN2 (0.61) FAAHMAPTMAPK1SMN1; SMN2LMNA
SCHEMBL3769563 0.78 FAAH (0.60) FAAHMAPTMAPK1SMN1; SMN2LMNA
SCHEMBL3767431 0.78 FAAH (0.60) FAAHMAPTMAPK1SMN1; SMN2LMNA
SCHEMBL3765693 0.77 LMNA (0.72) FAAHMAPTMAPK1SMN1; SMN2LMNA
SCHEMBL3764195 0.76 MAPT (0.60) FAAHMAPTMAPK1SMN1; SMN2LMNA
SCHEMBL9370494 0.73 LMNA (0.61) FAAHMAPK1SMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 FAAH 1/4885MAPT 3805/4885MAPK1 2636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.